BSTC BioSpecifics Technologies Corp

51.64
-0.01  -0%
Previous Close 51.65
Open 51.36
Price To book 6.20
Market Cap 370.31M
Shares 7,171,000
Volume 17,005
Short Ratio 5.08
Av. Daily Volume 29,938

SEC filingsSee all SEC filings

  1. 8-K - Current report 17831420
  2. 8-K - Current report 17831404
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17830954
  4. DEF 14A - Other definitive proxy statements 17796255
  5. 8-K - Current report 17773215

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Endo is currently performing a commercial assessment.
XIAFLEX
Plantar fibromatosis
Phase 2 topline data released June 2016 - endpoints met
XIAFLEX
Human lipomas
Phase 2b data released November 17, 2016. Met endpoints. Phase 3 planned for 2H 2017.
XIAFLEX
Edematous fibrosclerotic panniculopathy (“cellulite”)
Phase 2b trial did not meet endpoint. Endo is currently performing a commercial assessment.
XIAFLEX
Adhesive Capsulitis (“Frozen Shoulder syndrome”)

Latest News

  1. Pharma Stock With Triple-Digit Growth Forming Blotchy Base
  2. Biospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : May 18, 2017
  3. BioSpecifics posts 1Q profit
  4. BioSpecifics Technologies Corp. Reports First Quarter 2017 Financial Results
  5. Biospecifics Technologies Corp. – Value Analysis (NASDAQ:BSTC) : April 21, 2017
  6. Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : April 20, 2017
  7. BioSpecifics Technologies Corp. Initiates Phase 1 Clinical Trial of XIAFLEX for Treatment of Uterine Fibroids
  8. ETFs with exposure to Biospecifics Technologies Corp. : April 7, 2017
  9. Biospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : April 7, 2017
  10. BioSpecifics Technologies Corp. to Present at the 16th Annual Needham Healthcare Conference
  11. Biospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : March 24, 2017
  12. Biospecifics Technologies Corp. :BSTC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  13. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2016 Financial Results
  14. Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : March 13, 2017
  15. Biotechs Among 5 Stocks Setting Up for Major Breakouts
  16. Biospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : January 31, 2017
  17. BioSpecifics Technologies Corp. to Present at NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference
  18. Biospecifics Technologies Corp. – Value Analysis (NASDAQ:BSTC) : January 19, 2017

SEC Filings

  1. 8-K - Current report 17831420
  2. 8-K - Current report 17831404
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17830954
  4. DEF 14A - Other definitive proxy statements 17796255
  5. 8-K - Current report 17773215
  6. 8-K - Current report 17766637
  7. 8-K - Current report 17744702
  8. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17694671
  9. 8-K - Current report 17692181
  10. 8-K - Current report 17668660